Discontinued — last reported Q4 '21
Business Segments · Restructuring Charges
Covance Drug Development — Restructuring Charges
Labcorp Holdings Covance Drug Development — Restructuring Charges increased by 194.1% to $5M in Q4 2021 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ1 2015
Last reportedQ4 2021Feb 25, 2022
Rolls up toRestructuring Charges
How to read this metric
High charges indicate significant operational changes or management's response to market shifts.
Detailed definition
The total gross expenses recognized during a period for restructuring initiatives, such as workforce reductions or site...
Peer comparison
Similar to restructuring expenses reported by peers during organizational realignments.
Metric ID:
lh_segment_covance_drug_development_restructuring_chargesHistorical Data
3 periods
| Q2 '21 | Q3 '21 | Q4 '21 | |
|---|---|---|---|
| Value | $700K | $1.7M | $5M |
| QoQ Change | — | +142.9% | +194.1% |
Range$700K – $5M
Current Streak2+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — restructuring charges?
- Labcorp Holdings (LH) reported covance drug development — restructuring charges of $5M in Q4 2021.
- What does covance drug development — restructuring charges mean?
- Total costs recognized for restructuring the drug development segment.